Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Effects of Coenzyme Q10 (CoQ) in Parkinson Disease

Study:

Effects of Coenzyme Q10 in Parkinson Disease - Phase III

Rationale:

n/a

Purpose:

The purpose of this study is to evaluate the safety and effectiveness of high dosages of Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Parkinson Disease Drug: Coenzyme Q10 with vitamin E
Drug: placebo with vitamin E
Phase 3

Verified by Weill Medical College of Cornell University December, 2012

Sponsored by: Weill Medical College of Cornell University
Information provided by: Weill Medical College of Cornell University
ClinicalTrials.gov identifier: NCT00740714

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

The Cleveland Clinic Foundation, 9500 Euclid Avenue S-31
Cleveland, Ohio 44195
United States

M. Flint Beal, MD., Principal Investigator
David Oakes, PhD., Principal Investigator
Ira Shoulson, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site